a full approval or an accelerated approval
KalshiCheck availabilityKYC requiredVerified resolution dataWell calibratedSelected book midpoint
Yes · —
Loading selected book…
—
Stored price
Yes 82%
Yes 82%Market quality
38 / 100
Low quality24h Volume
—
Open interest
$633.6
Low open interestBid / Ask
— / —
YesSpread
—
Market data
Updated 9 minutes ago
Jun 17, 26, 9:00 PM UTCJan 1, 27, 4:59 AM UTC
Chart and changes show stored historical probabilities, not the selected live book.
Trends
Selected row: book midpoint. Other rows: stored references, possibly normalized; 24h changes use stored history.
Venue terms
Source: Kalshi
Informational venue terms only; CoinRithm paper trading uses its own rules.
- Early close:
- Yes
- Settlement timer:
- 30m (informational)
Market depth · Yes
Loading selected book…
—
Related Markets
Related questions for context, not a comparison of equivalent contracts.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)
KalshiFDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
KalshiMeasles cases in U.S. in 2026?
PolymarketWill a pneumonic plague case be reported in the U.S. this year?
KalshiRules
This outcome's exact rule is not available.
Settles via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.
Rules for each outcome
- Yes
- This outcome's exact rule is not available.
- No
- This outcome's exact rule is not available.